Today in Peak History (October 1-20)
Release time:
2020-08-14
peak (10# March 1 -20 )
1958 10 , while building the workshop, Jinhua county mobilized more than 600 cadres and members to Jinhua cement factory to build a small earth furnace group and produce cement by earth method.
◆ 1963 10 17 , after Jinhua Cement Plant stopped production for nearly two years, Zhejiang Provincial Planning Commission made a decision to resume production and allocated 10 yuan for resumption of production and supporting purposes.
◆ 1983 10 In April, Du Zihong was appointed director of Jinhua Cement Factory.
◆ 1990 10 , Peak 425# Ordinary Portland Cement passed the certification of China Cement Product Quality Certification Committee and became a national quality certification product.
◆ 1994 10 In early February, the large-scale documentary film "Peak of Endeavour" and the large-scale TV music feature film "Weiwei Peak Love", which reflected the reform achievements of Jianfeng Group, were released.
1994 10 15 , Jianfeng Brand 525# Ordinary Portland Cement passed the certification of China Cement Product Quality Certification Committee and became a national quality certification product.
1995 10 February 6 , Zhejiang Building Materials Corporation approved Jianfeng Group to produce 425#R ordinary Portland cement.
◆ 2000 10# In August, Wang Youfa, then general manager of the group company, was awarded the title of "National Model Worker in Building Materials System.
2003 10 16 , the signing ceremony of daye peak cement project was held in daye city, Hubei province.
2007 10 , the group company adopted the form of "double push and double examination" for the first time to carry out the recommendation and selection of reserve talents.
◆ 2011 10 , Cefmenoxime Hydrochloride for Injection and its raw materials produced by Jianfeng Pharmaceutical won the first prize of "Excellent New Industrial Products and New Technologies" in Zhejiang Province in 2011 .
2013 10# November and August, the group company carried out the selection of reserve talents. Since then, the selection of reserve talents will be carried out every two years, and the personnel who pass the selection will be included in the reserve talent pool of the group company, and the corresponding training and training will be carried out. When selecting cadres, each unit of the group will give priority to the selection of the reserve talent pool.
2013 October 12 June, Jianfeng Pharmaceutical Company was approved to set up a national postdoctoral research station in Jinhua, which is the third national postdoctoral research station of Jianfeng Pharmaceutical Company. ◆
10 April, Chairman of the Group Company Jiang Xiaomeng was named a national model worker in the building materials industry.
February 18 , the ceremony of Yunnan Jianfeng Cement Co., Ltd. donating money to establish Hope Primary School was held in Liushun Town Central Primary School in Pu 'er City, which is also the eighth Jianfeng Hope Primary School. ◆
October 152, Jianfeng Pharmaceutical's key innovative product "Yue Yining" (Aceclofenac Sustained Release Tablets) was awarded "China Pharmaceutical Enterprise Growth Product Brand" by the No. 153 27 National Pharmaceutical Economic Information Conference ". ◆ 2016
◆ 2017 10
◆ 2017 10 July
, Yunnan peak tons of packed cement were sent to Laos. This is the company tons of packaging cement for the first time out of the country. (Xu Xia finishing)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page